{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:04:18Z","timestamp":1783533858678,"version":"3.55.0"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T00:00:00Z","timestamp":1565481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Otago Medical Research Foundation - Southern Victorian Charitable Trust Summer Scholarship"},{"name":"Strategic Research Grant from the Department of Preventive and Social Medicine, University of Otago"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Clinical guidelines recommend the use of beta\u2010blockers and other cardiovascular prevention drugs in patients with acute coronary syndrome (ACS). Studies in several countries have found that beta\u2010blockers are underused in patients with chronic obstructive pulmonary disease (COPD) and co\u2010morbid heart disease, although most have only examined use in subgroups of patients. We undertook a nationwide follow\u2010up study in New Zealand to describe the use of beta\u2010blockers and other cardiovascular prevention drugs in patients with COPD and ACS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>National health and pharmaceutical dispensing data were used to derive the study cohort, identify patients who were admitted to hospital with ACS and\/or heart failure before cohort entry and during follow\u2010up, and ascertain drug use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study cohort included 83\u2009435 patients aged \u226545\u2009years, with 290\u2009400 person\u2010years of follow\u2010up. Among 2637 patients with \u22651 ACS admission during follow\u2010up, only 56.6% received a beta\u2010blocker in the 6 months following the first admission, while 87.7% and 81%, respectively, received aspirin and a statin. Patients with higher COPD severity were less likely to receive a beta\u2010blocker than those with lower severity, as were those with no history of previous ACS and\/or heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Use of beta\u2010blockers following an ACS admission was much lower than expected based on the findings of general audits of ACS management in New Zealand. Along with the higher proportions using aspirin and statins, and the differences in beta\u2010blocker dispensing by COPD severity, this suggests a particular reluctance to prescribe beta\u2010blockers to patients with COPD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.13662","type":"journal-article","created":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T19:06:02Z","timestamp":1565550362000},"page":"173-182","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Underuse of beta\u2010blockers by patients with COPD and co\u2010morbid acute coronary syndrome: A nationwide follow\u2010up study in New Zealand"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6824-6176","authenticated-orcid":false,"given":"Lianne","family":"Parkin","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology Research Network  Dunedin New Zealand"},{"name":"Department of Preventive and Social Medicine, Dunedin School of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Quon","sequence":"additional","affiliation":[{"name":"Dunedin School of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Sharples","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Research Network  Dunedin New Zealand"},{"name":"Department of Medicine, Dunedin School of Medicine University of Otago  Dunedin New Zealand"},{"name":"Department of Mathematics and Statistics University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barson","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Research Network  Dunedin New Zealand"},{"name":"Department of Preventive and Social Medicine, Dunedin School of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Dummer","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Research Network  Dunedin New Zealand"},{"name":"Department of Medicine, Dunedin School of Medicine University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,11]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Ministry of Health. Health loss in New Zealand 1990\u20132013: a report from the New Zealand Burden of Diseases Injuries and Risk Factors Study. Wellington: Ministry of Health 2016."},{"key":"e_1_2_9_3_1","unstructured":"Ministry of Health. Publicly funded hospital discharges \u2010 1 July 2014 to 30 June 2015. Wellington: Ministry of Health 2017."},{"key":"e_1_2_9_4_1","unstructured":"Ministry of Health. Mortality and demographic data 2012. Wellington: Ministry of Health 2015."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2847"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00518-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2032"},{"key":"e_1_2_9_8_1","volume-title":"New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners","author":"New Zealand Guidelines Group","year":"2009"},{"key":"e_1_2_9_9_1","volume-title":"New Zealand Primary Care Handbook 2012","author":"New Zealand Guidelines Group","year":"2012"},{"key":"e_1_2_9_10_1","first-page":"U1679","article-title":"ST\u2010elevation myocardial infarction: New Zealand management guidelines","volume":"118","author":"ST\u2010Elevation Myocardial Infarction Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand","year":"2005","journal-title":"N. Z. Med. J."},{"key":"e_1_2_9_11_1","first-page":"122","article-title":"New Zealand 2012 guidelines for the management of non ST\u2010elevation acute coronary syndromes","volume":"125","author":"Non ST\u2010Elevation Acute Coronary Syndrome Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand","year":"2012","journal-title":"N. Z. Med. J."},{"key":"e_1_2_9_12_1","first-page":"127","article-title":"ST\u2010elevation myocardial infarction: New Zealand management guidelines, 2013","volume":"126","author":"ST\u2010Elevation Myocardial Infarction Guidelines Group and the New Zealand Branch of Cardiac Society of Australia and New Zealand","year":"2013","journal-title":"N. Z. Med. J."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2016.06.789"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.019"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"e_1_2_9_17_1","volume-title":"Acute Coronary Syndrome","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2016"},{"key":"e_1_2_9_18_1","volume-title":"Myocardial Infarction: Cardiac Rehabilitation and Prevention of Further Cardiovascular Disease","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"e_1_2_9_19_1","first-page":"CD003566","article-title":"Cardioselective beta\u2010blockers for chronic obstructive pulmonary disease","volume":"4","author":"Salpeter S","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2549"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6650"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001611"},{"key":"e_1_2_9_23_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. 2018 report. [Accessed 31 July 2018.] Available from URL:http:\/\/goldcopd.org\/gold-reports\/"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13240"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci080"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309458"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20751"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S144333"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13795"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.05.004"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13235"},{"key":"e_1_2_9_32_1","unstructured":"Ministry of Health. Pharmaceutical Collection. [Accessed 31 July 2018.] Available from URL:http:\/\/www.health.govt.nz\/nz\u2010health\u2010statistics\/national\u2010collections\u2010and\u2010surveys\/collections\/pharmaceutical\u2010collection"},{"key":"e_1_2_9_33_1","unstructured":"Ministry of Health. National Minimum Dataset (hospital events). [Accessed 31 July 2018.] Available from URL:http:\/\/www.health.govt.nz\/nz-health-statistics\/national-collections-and-surveys\/collections\/national-minimum-dataset-hospital-events"},{"key":"e_1_2_9_34_1","unstructured":"Ministry of Health. Mortality Collection. [Accessed 31 July 2018.] Available from URL:http:\/\/www.health.govt.nz\/nz-health-statistics\/national-collections-and-surveys\/collections\/mortality-collection"},{"key":"e_1_2_9_35_1","unstructured":"Ministry of Health. National Health Index. [Accessed 31 July 2018.] Available from URL:http:\/\/www.health.govt.nz\/our-work\/health-identity\/national-health-index"},{"key":"e_1_2_9_36_1","volume-title":"NZDep2006 Index of Deprivation User's Manual","author":"Salmond C","year":"2007"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280206074463"},{"key":"e_1_2_9_38_1","unstructured":"EllisC GambleG DevlinG ElliottJ HamerA WilliamsM MatsisP TroughtonR RanasingheI FrenchJet al.;for the New Zealand Acute Coronary Syndromes Snapshot Audit Group. The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care.N. Z. Med. J.2013;126:36\u201368."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1071\/HC16013"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2017.04.010"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sup001"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.13662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/resp.13662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T18:42:50Z","timestamp":1694112170000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.13662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,11]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/resp.13662"],"URL":"https:\/\/doi.org\/10.1111\/resp.13662","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,11]]},"assertion":[{"value":"2018-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}